Nimesil (Nimesulide)

Nimesulide selectively inhibits the cyclo‑oxygenase‑2 (COX‑2) enzyme, decreasing the synthesis of prostaglandins that mediate inflammation, pain and fever. By reducing prostaglandin E2 levels, it limits peripheral nociceptor sensitisation and central fever signalling, providing analgesic and antipyretic effects while sparing COX‑1 activity that protects gastric mucosa.

The dosage of Nimesil is determined by the prescribing clinician based on the patient’s condition, age, weight and response. Nimesulide is supplied as 100 mg oral granules for suspension, and the prescriber specifies the amount and frequency appropriate for each individual case.

The safety of nimesulide in pregnancy and lactation has not been established. Current guidance advises avoiding its use during pregnancy, especially the third trimester, and during breastfeeding because potential risks to the fetus or infant cannot be excluded.

To place an order, submit an enquiry on the Nimesil product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective NSAIDs such as ibuprofen or diclofenac, nimesulide shows relative COX‑2 selectivity, which may reduce the incidence of gastrointestinal irritation while still providing effective analgesic and antipyretic activity. However, it carries its own risk profile, including potential hepatotoxicity, and should be selected based on individual patient factors and clinical judgement.

Nimesil oral granules should be stored at ambient temperature, below 25 °C, in the original container. Keep the product away from moisture, direct sunlight and heat sources to maintain stability and potency throughout its shelf life.

The granules are reconstituted with the supplied vehicle to form a suspension, which is then taken orally according to the prescriber’s instructions. The suspension should be shaken gently before each dose and measured with a calibrated dosing device to ensure accurate intake.

The most serious adverse reactions include hepatotoxicity, which can manifest as elevated liver enzymes or severe liver injury, and severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if signs of liver dysfunction or serious skin rash appear.

Nimesil is contraindicated in patients with known hypersensitivity to nimesulide or other NSAIDs, those with active peptic ulcer disease, severe hepatic impairment, and in pregnant women, especially during the third trimester. Caution is also advised for individuals with cardiovascular disease, renal insufficiency or uncontrolled hypertension.